These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
641 related articles for article (PubMed ID: 29587656)
1. Erlotinib treatment after platinum-based therapy in elderly patients with non-small-cell lung cancer in routine clinical practice - results from the ElderTac study. Brueckl WM; Achenbach HJ; Ficker JH; Schuette W BMC Cancer; 2018 Mar; 18(1):333. PubMed ID: 29587656 [TBL] [Abstract][Full Text] [Related]
2. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. Rosell R; Carcereny E; Gervais R; Vergnenegre A; Massuti B; Felip E; Palmero R; Garcia-Gomez R; Pallares C; Sanchez JM; Porta R; Cobo M; Garrido P; Longo F; Moran T; Insa A; De Marinis F; Corre R; Bover I; Illiano A; Dansin E; de Castro J; Milella M; Reguart N; Altavilla G; Jimenez U; Provencio M; Moreno MA; Terrasa J; Muñoz-Langa J; Valdivia J; Isla D; Domine M; Molinier O; Mazieres J; Baize N; Garcia-Campelo R; Robinet G; Rodriguez-Abreu D; Lopez-Vivanco G; Gebbia V; Ferrera-Delgado L; Bombaron P; Bernabe R; Bearz A; Artal A; Cortesi E; Rolfo C; Sanchez-Ronco M; Drozdowskyj A; Queralt C; de Aguirre I; Ramirez JL; Sanchez JJ; Molina MA; Taron M; Paz-Ares L; Lancet Oncol; 2012 Mar; 13(3):239-46. PubMed ID: 22285168 [TBL] [Abstract][Full Text] [Related]
3. Erlotinib in routine clinical practice for first-line maintenance therapy in patients with advanced non-small cell lung cancer (NSCLC). Faehling M; Achenbach J; Staib P; Steffen U; Tessen HW; Gaillard VE; Brugger W J Cancer Res Clin Oncol; 2018 Jul; 144(7):1375-1383. PubMed ID: 29687154 [TBL] [Abstract][Full Text] [Related]
4. A phase II trial of erlotinib monotherapy for pretreated elderly patients with advanced EGFR wild-type non-small cell lung cancer. Minemura H; Yokouchi H; Azuma K; Hirai K; Sekine S; Oshima K; Kanazawa K; Tanino Y; Inokoshi Y; Ishii T; Katsuura Y; Oishi A; Ishida T; Munakata M BMC Res Notes; 2015 Jun; 8():220. PubMed ID: 26043909 [TBL] [Abstract][Full Text] [Related]
5. Erlotinib plus bevacizumab versus erlotinib alone in patients with EGFR-positive advanced non-squamous non-small-cell lung cancer (NEJ026): interim analysis of an open-label, randomised, multicentre, phase 3 trial. Saito H; Fukuhara T; Furuya N; Watanabe K; Sugawara S; Iwasawa S; Tsunezuka Y; Yamaguchi O; Okada M; Yoshimori K; Nakachi I; Gemma A; Azuma K; Kurimoto F; Tsubata Y; Fujita Y; Nagashima H; Asai G; Watanabe S; Miyazaki M; Hagiwara K; Nukiwa T; Morita S; Kobayashi K; Maemondo M Lancet Oncol; 2019 May; 20(5):625-635. PubMed ID: 30975627 [TBL] [Abstract][Full Text] [Related]
7. Retrospective Assessment of a Serum Proteomic Test in a Phase III Study Comparing Erlotinib plus Placebo with Erlotinib plus Tivantinib (MARQUEE) in Previously Treated Patients with Advanced Non-Small Cell Lung Cancer. Buttigliero C; Shepherd FA; Barlesi F; Schwartz B; Orlov S; Favaretto AG; Santoro A; Hirsh V; Ramlau R; Blackler AR; Roder J; Spigel D; Novello S; Akerley W; Scagliotti GV Oncologist; 2019 Jun; 24(6):e251-e259. PubMed ID: 30139835 [TBL] [Abstract][Full Text] [Related]
8. Retrospective efficacy and safety analyses of erlotinib, pemetrexed, and docetaxel in EGFR-mutation-negative patients with previously treated advanced non-squamous non-small-cell lung cancer. Nishiyama A; Katakami N; Yoshioka H; Iwasaku M; Korogi Y; Hata A; Takeshita J; Otsuka K; Nishino K; Uchida J; Okuyama T; Namba Y; Mori M; Fujita S; Morita S Lung Cancer; 2015 Sep; 89(3):301-5. PubMed ID: 26141215 [TBL] [Abstract][Full Text] [Related]
9. Erlotinib versus vinorelbine plus cisplatin as adjuvant therapy in Chinese patients with stage IIIA EGFR mutation-positive non-small-cell lung cancer (EVAN): a randomised, open-label, phase 2 trial. Yue D; Xu S; Wang Q; Li X; Shen Y; Zhao H; Chen C; Mao W; Liu W; Liu J; Zhang L; Ma H; Li Q; Yang Y; Liu Y; Chen H; Wang C Lancet Respir Med; 2018 Nov; 6(11):863-873. PubMed ID: 30150014 [TBL] [Abstract][Full Text] [Related]
10. First-line erlotinib versus gemcitabine/cisplatin in patients with advanced EGFR mutation-positive non-small-cell lung cancer: analyses from the phase III, randomized, open-label, ENSURE study. Wu YL; Zhou C; Liam CK; Wu G; Liu X; Zhong Z; Lu S; Cheng Y; Han B; Chen L; Huang C; Qin S; Zhu Y; Pan H; Liang H; Li E; Jiang G; How SH; Fernando MCL; Zhang Y; Xia F; Zuo Y Ann Oncol; 2015 Sep; 26(9):1883-1889. PubMed ID: 26105600 [TBL] [Abstract][Full Text] [Related]
11. A prospective, multicenter phase II trial of low-dose erlotinib as maintenance treatment after platinum doublet chemotherapy for advanced non-small cell lung cancer harboring EGFR mutation. Hirano S; Naka G; Takeda Y; Iikura M; Hayama N; Yanagisawa A; Amano H; Nakamura M; Nakamura S; Tabeta H; Sugiyama H Chin Clin Oncol; 2016 Dec; 5(6):77. PubMed ID: 28061541 [TBL] [Abstract][Full Text] [Related]
12. Real-life effectiveness of erlotinib as second-line treatment of stage IIIB/IV squamous non-small cell lung cancer: Results of the PEPiTA observational study. Monnet I; Audigier-Valette C; Girard N; Vergnenègre A; Molinier O; Souquet PJ; Blanchon F; Bonnetain F; Taguieva-Pioger N; Lamour C; Wislez M Lung Cancer; 2016 Aug; 98():84-90. PubMed ID: 27393512 [TBL] [Abstract][Full Text] [Related]
13. Treatment Patterns by EGFR Mutation Status in Non-Small Cell Lung Cancer Patients in the USA: A Retrospective Database Analysis. Aguilar KM; Winfree KB; Muehlenbein CE; Zhu YE; Wilson T; Wetmore S; Nadler ES Adv Ther; 2018 Nov; 35(11):1905-1919. PubMed ID: 30341504 [TBL] [Abstract][Full Text] [Related]
14. Erlotinib and bevacizumab in patients with advanced non-small-cell lung cancer and activating EGFR mutations (BELIEF): an international, multicentre, single-arm, phase 2 trial. Rosell R; Dafni U; Felip E; Curioni-Fontecedro A; Gautschi O; Peters S; Massutí B; Palmero R; Aix SP; Carcereny E; Früh M; Pless M; Popat S; Kotsakis A; Cuffe S; Bidoli P; Favaretto A; Froesch P; Reguart N; Puente J; Coate L; Barlesi F; Rauch D; Thomas M; Camps C; Gómez-Codina J; Majem M; Porta R; Shah R; Hanrahan E; Kammler R; Ruepp B; Rabaglio M; Kassapian M; Karachaliou N; Tam R; Shames DS; Molina-Vila MA; Stahel RA; Lancet Respir Med; 2017 May; 5(5):435-444. PubMed ID: 28408243 [TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of erlotinib versus chemotherapy in second-line treatment of patients with advanced, non-small-cell lung cancer with poor prognosis (TITAN): a randomised multicentre, open-label, phase 3 study. Ciuleanu T; Stelmakh L; Cicenas S; Miliauskas S; Grigorescu AC; Hillenbach C; Johannsdottir HK; Klughammer B; Gonzalez EE Lancet Oncol; 2012 Mar; 13(3):300-8. PubMed ID: 22277837 [TBL] [Abstract][Full Text] [Related]
16. Erlotinib alone or with bevacizumab as first-line therapy in patients with advanced non-squamous non-small-cell lung cancer harbouring EGFR mutations (JO25567): an open-label, randomised, multicentre, phase 2 study. Seto T; Kato T; Nishio M; Goto K; Atagi S; Hosomi Y; Yamamoto N; Hida T; Maemondo M; Nakagawa K; Nagase S; Okamoto I; Yamanaka T; Tajima K; Harada R; Fukuoka M; Yamamoto N Lancet Oncol; 2014 Oct; 15(11):1236-44. PubMed ID: 25175099 [TBL] [Abstract][Full Text] [Related]
17. Maintenance erlotinib versus erlotinib at disease progression in patients with advanced non-small-cell lung cancer who have not progressed following platinum-based chemotherapy (IUNO study). Cicènas S; Geater SL; Petrov P; Hotko Y; Hooper G; Xia F; Mudie N; Wu YL Lung Cancer; 2016 Dec; 102():30-37. PubMed ID: 27987585 [TBL] [Abstract][Full Text] [Related]
18. Effectiveness of erlotinib treatment in advanced KRAS mutation-negative lung adenocarcinoma patients: Results of a multicenter observational cohort study (MOTIVATE). Sarosi V; Losonczy G; Francovszky E; Tolnay E; Torok S; Galffy G; Hegedus B; Dome B; Ostoros G Lung Cancer; 2014 Oct; 86(1):54-8. PubMed ID: 25129367 [TBL] [Abstract][Full Text] [Related]
19. Efficacy and safety of afatinib in Chinese patients with EGFR-mutated metastatic non-small-cell lung cancer (NSCLC) previously responsive to first-generation tyrosine-kinase inhibitors (TKI) and chemotherapy: comparison with historical cohort using erlotinib. Lee VH; Leung DK; Choy TS; Lam KO; Lam PM; Leung TW; Kwong DL BMC Cancer; 2016 Feb; 16():147. PubMed ID: 26911310 [TBL] [Abstract][Full Text] [Related]
20. EGFR-TKI rechallenge with bevacizumab in EGFR-mutant non-small cell lung cancer. Otsuka K; Hata A; Takeshita J; Okuda C; Kaji R; Masago K; Fujita S; Katakami N Cancer Chemother Pharmacol; 2015 Oct; 76(4):835-41. PubMed ID: 26349474 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]